2023 will be a tough year for pre-revenue biotech firms to go public in Hong Kong, according to Serena Shao, founder and managing partner of healthcare-focused investment firm Ascendum Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
